Abstract
Histone deacetylases (HDACs) play a significant role in the proliferation and dissemination of cancer and represent promising epigenetic drug targets. The HDAC inhibitor vorinostat featuring a zinc-binding hydroxamate fragment was already clinically approved. However, HDAC inhibitors containing hydroxamic acids are often hampered by acquired or intrinsic drug resistance and may lead to enhanced tumor aggressiveness. In order to overcome these drawbacks of hydroxamate HDAC inhibitors, a series of multimodal derivatives of this compound class, including such with different zinc-binding groups, was recently developed and showed promising anticancer activity. This review provides an overview of the chemistry and pleiotropic anticancer modes of action of these conceptually new HDAC inhibitors.
Keywords: Anticancer drugs, epigenetics, histone deacetylases, kinases, DNA targeting, HDAC inhibitors, hybrid molecules.
Current Cancer Drug Targets
Title:Multimodal HDAC Inhibitors with Improved Anticancer Activity
Volume: 18 Issue: 1
Author(s): Rainer Schobert and Bernhard Biersack*
Affiliation:
- Organic Chemistry Laboratory, Faculty of Biology, Chemistry and Earth Sciences, University of Bayreuth, Universitatsstrasse 30, 95440 Bayreuth,Germany
Keywords: Anticancer drugs, epigenetics, histone deacetylases, kinases, DNA targeting, HDAC inhibitors, hybrid molecules.
Abstract: Histone deacetylases (HDACs) play a significant role in the proliferation and dissemination of cancer and represent promising epigenetic drug targets. The HDAC inhibitor vorinostat featuring a zinc-binding hydroxamate fragment was already clinically approved. However, HDAC inhibitors containing hydroxamic acids are often hampered by acquired or intrinsic drug resistance and may lead to enhanced tumor aggressiveness. In order to overcome these drawbacks of hydroxamate HDAC inhibitors, a series of multimodal derivatives of this compound class, including such with different zinc-binding groups, was recently developed and showed promising anticancer activity. This review provides an overview of the chemistry and pleiotropic anticancer modes of action of these conceptually new HDAC inhibitors.
Export Options
About this article
Cite this article as:
Schobert Rainer and Biersack Bernhard*, Multimodal HDAC Inhibitors with Improved Anticancer Activity, Current Cancer Drug Targets 2018; 18 (1) . https://dx.doi.org/10.2174/1568009617666170206102613
DOI https://dx.doi.org/10.2174/1568009617666170206102613 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents on Cell Cycle Regulatory Proteins
Recent Patents on Biotechnology Mechanisms of Action and Chemical-Biological Interactions Between Ozone and Body Compartments: A Critical Appraisal of the Different Administration Routes
Current Drug Therapy Cationic Liposome Mediated Delivery of FUS1 and hIL-12 Coexpression Plasmid Demonstrates Enhanced Activity against Human Lung Cancer
Current Cancer Drug Targets Effects of the Natural Isoflavonoid Genistein on Growth, Signaling Pathways and Gene Expression of Matrix Macromolecules by Breast Cancer Cells
Mini-Reviews in Medicinal Chemistry The Biological Role of mTOR in the Pathogenesis of Solid Tumors: An Overview
Current Enzyme Inhibition Tip60: Main Functions and Its Inhibitors
Mini-Reviews in Medicinal Chemistry Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine
Current Pharmaceutical Design A Wnt-ow of Opportunity: Targeting the Wnt/β-Catenin Pathway in Breast Cancer
Current Drug Targets The Means to an End of Tumor Cell Resistance to Chemotherapeutic Drugs Targeting Thymidylate Synthase: Shoot the Messenger
Current Drug Targets Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Vaccines Explored in Patients with Non-Small Cell Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Interferon Therapy in Lung Cancer: Current Perspectives
Current Cancer Therapy Reviews Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress
Current Cancer Drug Targets Attenuated Oncolytic Measles Virus Strains as Cancer Therapeutics
Current Pharmaceutical Biotechnology Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Current Protein & Peptide Science Role of the Non-Neuronal Human Cholinergic System in Lung Cancer and Mesothelioma: Possibility of New Therapeutic Strategies
Current Medicinal Chemistry - Anti-Cancer Agents Development of Vasculature Targeting Strategies for the Treatment of Chronic Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy Acute Hypersensitivity Reactions to Chemotherapy Agents: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Stem Cell-Derived Microvesicles: A Cell Free Therapy Approach to the Regenerative Medicine
Current Biotechnology